Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Drugs that target pathogen public goods are robust against evolved drug resistance.

Pepper JW.

Evol Appl. 2012 Nov;5(7):757-61. doi: 10.1111/j.1752-4571.2012.00254.x.

2.

Defeating pathogen drug resistance: guidance from evolutionary theory.

Pepper JW.

Evolution. 2008 Dec;62(12):3185-91. doi: 10.1111/j.1558-5646.2008.00525.x. Epub 2008 Sep 18.

PMID:
18803686
3.

Why does drug resistance readily evolve but vaccine resistance does not?

Kennedy DA, Read AF.

Proc Biol Sci. 2017 Mar 29;284(1851). pii: 20162562. doi: 10.1098/rspb.2016.2562. Review.

4.

Protein promiscuity: drug resistance and native functions--HIV-1 case.

Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B.

J Biomol Struct Dyn. 2005 Jun;22(6):615-24.

PMID:
15842167
6.

The evolution of bacterial social life: From the ivory tower to the front lines of public health.

Pepper JW.

Evol Med Public Health. 2014 Jan;2014(1):65-8. doi: 10.1093/emph/eou010. Epub 2014 Mar 12.

7.

The evolution of antibiotic resistance: insight into the roles of molecular mechanisms of resistance and treatment context.

Maclean RC, Hall AR, Perron GG, Buckling A.

Discov Med. 2010 Aug;10(51):112-8. Review.

8.

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.

Nature. 1993 Feb 18;361(6413):650-4. Erratum in: Nature. 1993 Aug 19;364(6439):679.

PMID:
7679778
9.
10.

Cancer stem cells as 'units of selection'.

Greaves M.

Evol Appl. 2013 Jan;6(1):102-8. doi: 10.1111/eva.12017. Epub 2012 Oct 23.

11.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
14.

Evolution of antifungal-drug resistance: mechanisms and pathogen fitness.

Anderson JB.

Nat Rev Microbiol. 2005 Jul;3(7):547-56. Review.

PMID:
15953931
15.

Predicting protein evolution in vitro by phage escape technology.

Rohrbach AS, Dickerson TJ.

Mol Biosyst. 2009 Feb;5(2):128-33. doi: 10.1039/b814768j. Epub 2008 Dec 10. Review.

PMID:
19156257
16.

Theory for the evolution of diffusible external goods.

Driscoll WW, Pepper JW.

Evolution. 2010 Sep;64(9):2682-7. doi: 10.1111/j.1558-5646.2010.01002.x.

PMID:
20394658
17.

The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus.

Luciani F, Alizon S.

PLoS Comput Biol. 2009 Nov;5(11):e1000565. doi: 10.1371/journal.pcbi.1000565. Epub 2009 Nov 13.

18.

Group-size diversity in public goods games.

Peña J.

Evolution. 2012 Mar;66(3):623-36. doi: 10.1111/j.1558-5646.2011.01504.x. Epub 2011 Dec 21.

PMID:
22380428
19.

Evolutionary epidemiology 20 years on: challenges and prospects.

Restif O.

Infect Genet Evol. 2009 Jan;9(1):108-23. doi: 10.1016/j.meegid.2008.09.007. Epub 2008 Oct 14. Review.

PMID:
18977460
20.

Drug resistance, virus fitness and HIV-1 mutagenesis.

Chen R, Quinones-Mateu ME, Mansky LM.

Curr Pharm Des. 2004;10(32):4065-70. Review.

PMID:
15579088

Supplemental Content

Support Center